The objective of this study is to assess the relative bioavailability of two test tablet formulations of ABT-450 as compared to the ABT-450 hard gelatin capsule formulation as a reference.

This is a two part study. Part 1 is a single dose, three period, complete crossover study in approximately 21 subjects. Part 2 is a single dose, two period, complete crossover study in approximately 20 subjects.

Inclusion Criteria

• Overall healthy subjects
• Non-childbearing potential females included

Exclusion Criteria

• Positive test for HAV IgM, HBsAg, anti-HCV Ab or anti-HIV Ab
• Clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder
• Use of tobacco or nicotine-containing products with the 6-month period prior to study drug administration
• Abnormal screening laboratory results that are considered clinically significant by the investigator
• Pregnant or breastfeeding female; requirement for any OTC and/or prescription medication, vitamins and/or herbal supplements on a regular basis
• Previous exposure to ABT-450